Prenuvo Welcomes Jill Woodworth, Former Peloton CFO, As Chief Financial Officer

Woodworth helped lead Peloton from pre-IPO to $4B+ in revenue, now she’s bringing that experience to a pioneer in proactive health REDWOOD CITY, Calif.–(BUSINESS WIRE)–Prenuvo, a leader in proactive whole-body MRI screening, today announced the appointment of Jill Woodworth as Chief Financial Officer. A seasoned financial executive with deep experience leading high-growth companies through IPO … [Read more…]

Polymer Additive Manufacturing Industry Research 2024-2031: Growing Demand for On-demand Production and Spare Parts Manufacturing, & Expansion of AM in Healthcare Applications – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Polymer Additive Manufacturing Market Size, Share, Forecast, & Trends Analysis by Offering (Hardware, Materials, Services), Technology (FDM, SLA, SLS, Polyjet, Binder Jetting), End User (Consumer, Electronics, Healthcare, Automotive, Aerospace & Defense) – Global Forecast to 2031” report has been added to ResearchAndMarkets.com’s offering. The Polymer Additive Manufacturing Market was valued at $11.95 billion … [Read more…]

Merck Announces Phase 3 KEYNOTE-B96 Trial Met Primary Endpoint of Progression-Free Survival (PFS) in Patients With Platinum-Resistant Recurrent Ovarian Cancer Whose Tumors Expressed PD-L1 and in All Comers

Study also met secondary endpoint of overall survival (OS) for patients whose tumors express PD-L1 KEYTRUDA® (pembrolizumab) plus chemotherapy (paclitaxel) with or without bevacizumab is the first immune checkpoint inhibitor-based regimen to show a statistically significant improvement in OS for ovarian cancer RAHWAY, N.J.–(BUSINESS WIRE)–$MRK #MRK–Merck (NYSE: MRK), known as MSD outside of the United … [Read more…]

Three-month interim report (Q1) 2025 (Unaudited): LEO Pharma Delivers 9% Revenue Growth at Constant Exchange Rates and Doubles Adjusted EBITDA Margin to 16%

BALLERUP, Denmark–(BUSINESS WIRE)–In Q1, LEO Pharma continued its robust growth, driven by dermatology, and made significant strategic progress. This included expanding the launch of Anzupgo® to five markets, advancing innovation through the newly formed strategic partnership with Gilead for the STAT6 program, and significantly improving profitability with a return to a positive net profit. Q1 … [Read more…]

Microba Announces Landmark GI Study Results From Over 4,600 Patients

Results at a glance: 71.4% of MetaXplore™ reports from 4,616 patients identified actionable results 41.9% tested positive for abnormal microbiome markers linked to gastrointestinal health 9.9% tested positive for gastrointestinal markers, including inflammation, pancreatic insufficiency, or blood in stool 19.6% of reports tested positive for multiple markers (microbiome and gastrointestinal) 65% of patients reported health … [Read more…]

Rubedo Life Sciences’ Drug Discovery Platform, ALEMBIC™, Helps Identify Senescent or “Zombie” Neurons in New Study Linking Neuropathic Pain and Aging Published in Peer-Reviewed Scientific Journal Nature Neuroscience

Study is the first demonstration of senescent neurons driving neuropathic pain1 Rubedo’s proprietary, AI-driven drug discovery platform ALEMBIC™ identified senescent neurons as novel therapeutic targets2 SAN FRANCISCO–(BUSINESS WIRE)–Rubedo Life Sciences, Inc. (Rubedo), an AI-driven, clinical-stage biotech focused on discovering and rapidly developing selective cellular rejuvenation medicines targeting aging cells, today announced that using open source … [Read more…]

FDA Approves Merck’s WELIREG® (belzutifan) for the Treatment of Adults and Pediatric Patients 12 Years and Older With Locally Advanced, Unresectable, or Metastatic Pheochromocytoma or Paraganglioma (PPGL)

WELIREG becomes the only approved and available treatment in the U.S. for eligible patients with advanced PPGL RAHWAY, N.J.–(BUSINESS WIRE)–$MRK #MRK–Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the U.S. Food and Drug Administration (FDA) has approved WELIREG® (belzutifan), Merck’s oral hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor, for the … [Read more…]

IPS HEART Granted Orphan Drug Designation in the EU for Becker Muscular Dystrophy

HOUSTON–(BUSINESS WIRE)–IPS HEART has been awarded Orphan Drug Designation (ODD) in the EU by the EUROPEAN MEDICINES AGENCY for GIVI-MPCs unique ability to create new muscle with 100% full length dystrophin in Becker Muscular Dystrophy (BMD). IPS HEART has now shown GIVI-MPCs can create new human muscle with full length human dystrophin in BMD dystrophic … [Read more…]

San Diego Fertility Center Launches Summer Promotion Offering $2,000 Off IVF Cycles and Discounted Medications

SAN DIEGO–(BUSINESS WIRE)–San Diego Fertility Center (SDFC), named the #1 fertility clinic in California by Newsweek in 2024, is helping families take the next step toward parenthood with a limited-time summer promotion. Patients who begin in vitro fertilization (IVF) cycles in July or August will receive $2,000 off their IVF cycle, plus additional savings on … [Read more…]

Leqembi Research Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts 2019-2024, 2024-2029F, 2034F – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Leqembi Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts” report has been added to ResearchAndMarkets.com’s offering. This Leqembi market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical … [Read more…]